Roche Holding AG $RHHBY is Saratoga Research & Investment Management’s 8th Largest Position

Saratoga Research & Investment Management lessened its stake in shares of Roche Holding AG (OTCMKTS:RHHBY) by 4.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,832,770 shares of the company’s stock after selling 87,315 shares during the quarter. Roche comprises about 5.0% of Saratoga Research & Investment Management’s holdings, making the stock its 8th biggest holding. Saratoga Research & Investment Management’s holdings in Roche were worth $94,516,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. S&CO Inc. lifted its position in shares of Roche by 2.5% during the 4th quarter. S&CO Inc. now owns 53,444 shares of the company’s stock worth $2,767,000 after buying an additional 1,290 shares during the last quarter. HighPoint Advisor Group LLC lifted its position in shares of Roche by 55.3% during the 4th quarter. HighPoint Advisor Group LLC now owns 16,515 shares of the company’s stock worth $852,000 after buying an additional 5,882 shares during the last quarter. Verity Asset Management Inc. lifted its position in shares of Roche by 26.4% during the 4th quarter. Verity Asset Management Inc. now owns 13,886 shares of the company’s stock worth $716,000 after buying an additional 2,896 shares during the last quarter. Oakworth Capital Inc. lifted its position in shares of Roche by 20.8% during the 4th quarter. Oakworth Capital Inc. now owns 1,658 shares of the company’s stock worth $86,000 after buying an additional 285 shares during the last quarter. Finally, Meritage Portfolio Management purchased a new stake in shares of Roche during the 4th quarter worth approximately $4,372,000.

Roche Stock Down 0.4%

Shares of Roche stock opened at $51.09 on Friday. The company has a quick ratio of 1.12, a current ratio of 1.38 and a debt-to-equity ratio of 0.72. The firm’s fifty day simple moving average is $50.70 and its 200-day simple moving average is $51.33. Roche Holding AG has a 12 month low of $37.51 and a 12 month high of $60.85.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on RHHBY. Citigroup began coverage on shares of Roche in a research report on Tuesday, January 27th. They set a “buy” rating for the company. Wolfe Research restated an “outperform” rating on shares of Roche in a research report on Thursday, February 26th. Morgan Stanley upgraded shares of Roche from an “underweight” rating to an “equal weight” rating and set a $46.00 price objective for the company in a research report on Friday, April 24th. TD Cowen restated a “hold” rating on shares of Roche in a research report on Tuesday, February 10th. Finally, Argus raised shares of Roche from a “hold” rating to a “buy” rating in a report on Monday, April 6th. Five analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $51.50.

Roche Company Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.